Evidence map›Paper›PMID 39625488›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2025

Protective effect of deinoxanthin in sorafenib-induced nephrotoxicity in rats with the hepatocellular carcinoma model.

Nilgun Karasu, Mehmet Kuzucu, Ozge Cengiz Mat, Mustafa Gul, Arzu Yay, Munis Dundar

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nilgun KarasuFaculty of Medicine, Department of Medical Genetics, Erciyes University, Kayseri, Turkey.
Mehmet KuzucuFaculty of Arts and Sciences, Department of Biology, Erzincan Binali Yıldırım University, Erzincan, Turkey.
Ozge Cengiz MatFaculty of Medicine, Department of Histology and Embryology, Erciyes University, Kayseri, Turkey.
Mustafa GulFaculty of Medicine, Department of Physiology, Ataturk University, Erzurum, Turkey.
Arzu YayFaculty of Medicine, Department of Histology and Embryology, Erciyes University, Kayseri, Turkey.
Munis DundarFaculty of Medicine, Department of Medical Genetics, Erciyes University, Kayseri, Turkey. dundar@erciyes.edu.tr.ORCID 0000-0003-0969-4611

Funding

Erciyes University Scientific Research Projects (BAP) unit TDK-2020-10342
6 · The paper itself

Abstract

Sorafenib is a synthetic compound and an orally administered multichines inhibitor that targets growth signaling and angiogenesis. It is widely recognized as the standard of care for advanced hepatocellular carcinoma (HCC) but has toxic side effects. Deinoxanthin, purified from the radioresistant bacterium Deinococcus radiodurans, has strong antioxidant characteristics. In this study, the protective effect of deinoxanthin against sorafenib-induced nephrotoxicity was investigated in a rat model of hepatocellular carcinoma. In this regard, the expressions of DDAH1, KIM1, and INOS genes were examined, histopathological and immunohistochemical analyses were performed, and various parameters such as SOD, MDA, GST, CAT, TAS, and TOS were tested biochemically. BUN and creatinine levels were measured in renal tissues. RT-qPCR, Western blot, and ELISA methods were used for all these analyses. As a result, the analyses show that deinoxanthin, which has a high antioxidant capacity, reduces kidney injury and can be used as a protective agent. The primary objective of this study is to evaluate the potential of deinoxanthin as a protective agent against the nephrotoxic side effects of sorafenib in HCC. Our study identified the potential synergistic effects of sorafenib and deinoxanthin on nephrotoxicity in rats with hepatocellular carcinoma.

Indexed as

Antineoplastic AgentsAntioxidantsCarcinoma, HepatocellularKidney DiseasesLiver NeoplasmsSorafenibAnimalsDisease Models, AnimalKidneyMaleRatsRats, WistarAntineoplastic AgentsAntioxidantsSorafenibDeinoxanthinHCCNephrotoxicitySorafenibSynergistic effect

Identifiers

PMID39625488

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.